Cellectis Is A Biotechnology Company Based In Parisfrancefounded In 1999 By Andrachoulika And David Sourdivethe Company Specializes In Gene Editing And Is Focused On Developing Allogeneic Car T Cell Therapies For Cancer Treatmentcellectis Utilizes Its Proprietary Talenatechnology And Pulseagile Electroporation System To Create Innovative Therapiesthe Company Went Public In 2007 And Is Listed On Nasdaq Since 2014 Cellectis Offers Precision Gene Editing Tools And A Range Of Allogeneic Car T Cell Therapiesincluding Ucart19Ucart22And Ucart20Awhich Target Various Cancersthe Company Collaborates With Pharmaceutical Partners Like Servier And Healthcare Institutions Such As Md Anderson Cancer Center To Advance Its Therapieswith Manufacturing Facilities In Parisnew Yorkand Raleighnccellectis Aims To Provide Cost Effective And Universally Accessible Cancer Treatmentsemphasizing Scalable Production And Off The Shelf Solutions
